N20 THE REALITY LAYER
The Capital Stack Behind Frontier Progress
Different uncertainties deserve different capital, terms and time horizons.
IN THIS NOTE · NOVEMBER 2025
Frontier projects are often financed as if one pool of capital should carry every risk from early uncertainty to scaled operation. A better model matches each stage with investors or lenders equipped to understand it.
Risk changes by stage
Early science carries technical uncertainty and limited collateral. Grants, mission-aligned capital and equity can absorb this. Proven assets with contracts may support equipment finance, infrastructure debt or project structures. Mixing the stages obscures risk and raises the cost of capital.
The transition matters. A scientific milestone or customer commitment can change which capital becomes available, but only when the evidence is credible.
Contracts are financing instruments
Long-term commitments can make infrastructure assets financeable. Licenses, options and milestone agreements can shape biotech economics. In each case, contract quality depends on counterparty strength, enforceability, conditions and delivery obligations.
A signed document does not eliminate execution risk. It redistributes it.
Capital should retire a named risk
The most useful financing plan states which uncertainty each tranche addresses and what evidence unlocks the next. This makes progress inspectable and protects both operator and capital provider from narratives that expand faster than proof.
Frontier progress is expensive. It becomes less wasteful when the capital stack mirrors the risk stack.
Match capital to the uncertainty it can bear
Different capital instruments are comfortable with different unknowns. Grants can support public knowledge without a near-term commercial return. Equity can absorb technical and market uncertainty in exchange for upside. Equipment finance prefers identifiable assets and recoverable value. Project or structured capital looks for contracted cash flow and controlled completion risk. Community funding may accept mission risk while requiring transparent milestones and participation rights.
Problems arise when the instrument's clock conflicts with the program. Short-duration debt cannot patiently wait for an uncertain biological result. Highly dilutive equity is expensive for a predictable asset deployment. A token market may update continuously while the underlying experiment needs months. The financing plan should therefore map each tranche to a risk that can be retired inside the instrument's time horizon and to an artifact the capital provider can actually evaluate.
Covenants are operating design
Financing terms do more than divide returns. Draw conditions, reporting duties, reserve requirements, collateral, milestone approvals and step-in rights shape how the project operates under stress. Poorly designed covenants can force a team to optimize for a superficial metric or conceal a delay until options disappear. Well-designed ones make important state changes visible early enough for capital and operations to respond.
The best reporting package is built from the same evidence the team uses to manage the work. It separates budget spent from risk retired, contract signed from delivery accepted and experiment run from conclusion supported. This reduces the gap between investor narrative and operating reality. Capital becomes productive when it funds a specific transition and receives evidence precise enough to distinguish a normal setback from a broken thesis.
- Match capital duration and return expectations to the maturity stage.
- Name the risk each tranche is intended to retire.
- Evaluate contract quality and delivery obligations together.
I would revise this if undifferentiated pools of capital consistently financed frontier projects more efficiently across every maturity stage.
Primary and institutional sources used as the grounding layer. Interpretation and synthesis are Luca's.
01